

Benign Prostatic Hyperplasia (BPH) Drugs-India Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BC924DEC201MEN.html>

Date: May 2018

Pages: 130

Price: US\$ 2,980.00 (Single User License)

ID: BC924DEC201MEN

Abstracts

Report Summary

Benign Prostatic Hyperplasia (BPH) Drugs-India Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Benign Prostatic Hyperplasia (BPH) Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole India and Regional Market Size of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017, and development forecast 2018-2023

Main market players of Benign Prostatic Hyperplasia (BPH) Drugs in India, with company and product introduction, position in the Benign Prostatic Hyperplasia (BPH) Drugs market

Market status and development trend of Benign Prostatic Hyperplasia (BPH) Drugs by types and applications

Cost and profit status of Benign Prostatic Hyperplasia (BPH) Drugs, and marketing status

Market growth drivers and challenges

The report segments the India Benign Prostatic Hyperplasia (BPH) Drugs market as:

India Benign Prostatic Hyperplasia (BPH) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North India

Northeast India

East India

South India

West India

India Benign Prostatic Hyperplasia (BPH) Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alpha-blocker

Phosphodiesterase Type-5 Inhibitors

5-alpha-Reductase Inhibitors

India Benign Prostatic Hyperplasia (BPH) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Clinics

Others

India Benign Prostatic Hyperplasia (BPH) Drugs Market: Players Segment Analysis (Company and Product introduction, Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Bayer HealthCare

Bristol-Myers Squibb

Valeant Pharmaceuticals

Endo Pharmaceuticals

Foresee Pharmaceuticals

Madrigal Pharmaceuticals

Merck

Novartis

Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Teva
Advaxis
ANI Pharmaceuticals
BHR Pharma

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 1.1 Definition of Benign Prostatic Hyperplasia (BPH) Drugs in This Report
- 1.2 Commercial Types of Benign Prostatic Hyperplasia (BPH) Drugs
 - 1.2.1 Alpha-blocker
 - 1.2.2 Phosphodiesterase Type-5 Inhibitors
 - 1.2.3 5-alpha-Reductase Inhibitors
- 1.3 Downstream Application of Benign Prostatic Hyperplasia (BPH) Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Others
- 1.4 Development History of Benign Prostatic Hyperplasia (BPH) Drugs
- 1.5 Market Status and Trend of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2023
 - 1.5.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Benign Prostatic Hyperplasia (BPH) Drugs in United States 2013-2017
- 2.2 Consumption Market of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Regions
 - 2.2.1 Consumption Volume of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Regions
 - 2.2.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Regions
- 2.3 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Regions
 - 2.3.1 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in New England 2013-2017
 - 2.3.2 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in The West

2013-2017

2.3.5 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in The South

2013-2017

2.3.6 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in Southwest

2013-2017

2.4 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in United States 2018-2023

2.4.1 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in United States 2018-2023

2.4.2 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Types

3.1.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Downstream Industry

4.2 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in New England

4.2.2 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in The Midwest

4.2.4 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in The West

4.2.5 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in The South

4.2.6 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in Southwest

4.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

5.1 United States Economy Situation and Trend Overview

5.2 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Major Players

6.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in United States by Major Players

6.3 Basic Information of Benign Prostatic Hyperplasia (BPH) Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Benign Prostatic Hyperplasia (BPH) Drugs Major Players

6.3.2 Employees and Revenue Level of Benign Prostatic Hyperplasia (BPH) Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Astellas Pharma

- 7.1.1 Company profile
- 7.1.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
- 7.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
- 7.2 Eli Lilly
 - 7.2.1 Company profile
 - 7.2.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.3 GlaxoSmithKline
 - 7.3.1 Company profile
 - 7.3.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.3.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.4 Sanofi
 - 7.4.1 Company profile
 - 7.4.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 7.5 ADC Therapeutics
 - 7.5.1 Company profile
 - 7.5.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of ADC Therapeutics
- 7.6 Bayer HealthCare
 - 7.6.1 Company profile
 - 7.6.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.6.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
- 7.7 Bristol-Myers Squibb
 - 7.7.1 Company profile
 - 7.7.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.7.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 7.8 Valeant Pharmaceuticals
 - 7.8.1 Company profile
 - 7.8.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.8.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals

7.9 Endo Pharmaceuticals

7.9.1 Company profile

7.9.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.9.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals

7.10 Foresee Pharmaceuticals

7.10.1 Company profile

7.10.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.10.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Foresee Pharmaceuticals

7.11 Madrigal Pharmaceuticals

7.11.1 Company profile

7.11.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.11.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Madrigal Pharmaceuticals

7.12 Merck

7.12.1 Company profile

7.12.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.12.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Merck

7.13 Novartis

7.13.1 Company profile

7.13.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.13.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Novartis

7.14 Spectrum Pharmaceuticals

7.14.1 Company profile

7.14.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.14.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Spectrum Pharmaceuticals

7.15 Takeda Pharmaceuticals

7.15.1 Company profile

7.15.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.15.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals

7.16 Teva

7.17 Advaxis

7.18 ANI Pharmaceuticals

7.19 BHR Pharma

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 8.1 Industry Chain of Benign Prostatic Hyperplasia (BPH) Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 9.1 Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.2 Raw Materials Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.3 Labor Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.4 Manufacturing Expenses Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources

12.2.2 Primary Sources
12.3 Reference

I would like to order

Product name: Benign Prostatic Hyperplasia (BPH) Drugs-India Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BC924DEC201MEN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC924DEC201MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

